Eisai has presented new clinical data from a post-hoc sub-group analysis of the Clarity AD open-label extension for lecanemab at the 98th Congress of the German Society of Neurology in Berlin.
The analysis focused on adult patients with early Alzheimer’s disease who are apolipoprotein E ε4 non-carriers or heterozygotes.
Participants who received treatment from the start through to 48 months (n=409) continued to accrue benefit over time, with sustained separation from the Alzheimer’s Disease Neuroimaging Initiative cohort (n=79).
Ongoing treatment with lecanemab also reduced the risk of progression to the next stage of Alzheimer’s disease by 32% over 48 months, as measured by CDR-SB.
Robert Sands, VP, Head of Medical Affairs, Eisai EMEA, said: “The presentation of these findings adds to the growing body of evidence demonstrating the potential benefits of lecanemab for eligible patients. As Alzheimer’s disease is a progressive and chronic condition, it is crucial to continue generating and analysing long-term data as it deepens our understanding of continuous treatment over time.”
He added: “Eisai is committed to investing in research and innovation, with the aim of being a part of the solution for a better future for those impacted by this disease.”
In the EU and UK, lecanemab is indicated for patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease who are ApoE ε4 non-carriers or heterozygotes with confirmed amyloid pathology. Common adverse reactions include infusion-related reaction (26%), ARIA-H (13%), fall (11%), headache (11%) and ARIA-E (9%).
